This case report highlights a challenging clinical dilemma to administer antiretroviral therapy in a critically-ill human immunodeficiency virus-infected patient who presented with multiple opportunistic infections and a non-functional gastrointestinal tract. The need for parenteral antiretroviral drug options is discussed and investigational drugs are briefly reviewed.
VellaSSchwartländerBSowSP. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS2012; 26(10): 1231–1241.
2.
MontanerJSReissPCooperD. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA1998; 279(12): 930–937.
3.
HammerSMSquiresKEHughesMD. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med1997; 337(11): 725–733.
4.
U.S. Department of Health and Human Services. Information on HIV/AIDS-related drugs. http://aidsinfo.nih.gov/drugs (accessed 26 April 2014).
5.
RobertsonD. US FDA approves new class of HIV therapeutics. Nat Biotechnol2003; 21(5): 470–471.
6.
NunnASda FonsecaEMBastosFI. AIDS treatment in Brazil: impacts and challenges. Health Aff (Millwood)2009; 28(4): 1103–1113.
7.
BoffitoMJacksonAOwenA. New Approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs2014; 74: 7–13.
8.
GautamNRoyUBalkundiS. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother2013; 1(57): 3110–3120.
9.
BaertLvan't KloosterGDriesW. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm2009; 72(3): 502–508.
10.
van ’t KloosterGHoebenEBorghysH. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother2010; 54(5): 2042–2050.
11.
Jackson A, et al. Rilpivirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV-females and rectum in males. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 35, 2012 [Original abstract not available]. Reference to abstract on article by Jared Baeten and Connie Celum. http://www.natap.org/2014/CROI/croi_78.htm (accessed 26 April 2014).
12.
RoyUMcMillanJAlnoutiY. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1–infected human peripheral blood lymphocyte–reconstituted mice. J Infect Dis2012; 206(10): 1577–1588.
13.
Spreen W, Williams P, Margolis D, et al. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults [Abstract]. In: 7th IAS conference on HIV pathogenesis, treatment and prevention. Kuala Lumpur, Malaysia, 30 June–3 July 2013. http://pag.ias2013.org/Abstracts.aspx?AID=796 (accessed 26 April 2014).
14.
FordSLGouldEChenS. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother2013; 57(11): 5472–5477.
KuritzkesDRJacobsonJPowderlyWG. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis2004; 189(2): 286–291.
17.
JacobsonJMKuritzkesDRGodofskyE. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother2009; 53(2): 450–457.
18.
MurgaJFrantiMPevearDC. Potent antiviral synergy between monoclonal antibody and small molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother2006; 50(10): 3289–3296.
19.
JacobsonJMSaagMSThompsonMA. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV infected adults. J Infect Dis2008; 198(9): 1345–1352.
20.
JacobsonJMThompsonMALalezariJP. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO140, a CCR5 monoclonal antibody. J Infect Dis2010; 201(10): 1481–1487.
21.
SwindellsSFlexnerCFletcherCV. The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis2011; 204(5): 669–674.
